Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
Philip C. Prorok(National Cancer Institute), John K. Gohagan(National Institutes of Health), Wilmer M. Rutt(Henry Ford Health System), Richard B. Hayes(New York University), Edward P. Gelmann(University of Arizona), Christine Cole Johnson(Henry Ford Health System), Joel L. Weissfeld(University of Pittsburgh), Ronald Fogel(Henry Ford Health System), Saundra S. Buys(University of Utah), Lance Yokochi(National Institutes of Health), David Chia(University of California, Los Angeles), Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Marsha Hasson(Westat (United States)), Jack S. Mandel(Exponent (United States)), Douglas J. Reding(Ascension), Martin M. Oken(Minneapolis Heart Institute Foundation), E. David Crawford(University of Colorado Health), Sameer Rafla(Brooklyn College), Barbara O’Brien(National Institutes of Health), Albert Oberman(University of Alabama at Birmingham), Robert S. Bresalier(The University of Texas MD Anderson Cancer Center)
Cited by 1,045
Related Papers
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
|New England Journal of Medicine|1993|3.3k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer
|New England Journal of Medicine|2000|1.4k
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
|Nature Genetics|2007|1.1k